Product/Composition:- | Allopurinol tablets |
---|---|
Strength:- | 100 mg, 300 mg |
Form:- | Oral Tablets |
Reference Brands:- | Aloprim(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Allopurinol inhibits xanthine oxidase, reducing uric acid production. It prevents gout flare-ups, kidney stones, and urate crystal formation. Benefits include long-term uric acid control, decreased gout attacks, kidney protection, and improved quality of life. It’s a key drug for managing hyperuricemia and gout complications.
Allopurinol tablets are approved in the EU and US for managing hyperuricemia and gout. In the EU, brands like Zyloric (by Sanofi) are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical data and biosimilarity, with generic options available. Both regions require detailed dossiers for approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for allopurinol tablets, ensuring adherence to European and American standards for safe, effective long-term uric acid management and gout prevention.